新辅助剂与辅助剂化学免疫疗法用于II-IIIB阶段的非小细胞肺癌
Russell Seth Martins1, Syed Shahzad Razi1, Ahmed Alnajar2
1Division of Thoracic Surgery, Department of Surgery, JFK University Medical Center, Hackensack Meridian Health, Edison, New Jersey.
The Annals of thoracic surgery
|January 30, 2024
概括
新辅助化学免疫疗法对可切除非小细胞肺癌 (NSCLC) 的辅助治疗提供了显著的生存优势. 这一发现表明,对于需要全身治疗的患者,应强烈考虑新辅助疗法.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 临床试验 临床试验
背景情况:
- 最近的试验表明,化疗免疫疗法在新辅助和辅助环境中改善了可切除非小细胞肺癌 (NSCLC) 的存活率.
- 对于NSCLC,新辅助和辅助化学免疫治疗方案之间没有直接的比较.
- 这项研究直接比较了新辅助药与辅助化学免疫疗法在可切除II-IIIBNSCLC的II-IIIBNSCLC.
研究的目的:
- 在可切除II-IIIB阶段非小细胞肺癌 (NSCLC) 患者中,比较新辅助与辅助化学免疫疗法的疗效.
- 为了评估新辅助剂与辅助化学免疫疗法相比,新辅助剂的整体生存 (OS) 益处.
- 评估治疗时间对切除性NSCLC的瘤结局的影响.
主要方法:
- 利用国家癌症数据库识别2015-2020年期间治疗的II-IIIB期NSCLC患者.
- 采用反向概率权重来调整混变量.
- 在术后3年使用卡普兰-梅尔曲线和考克斯回归分析了整体存活率 (OS).
主要成果:
- 权重队列包括2119名患者 (1034名新辅助,1085名辅助).
- 与辅助疗法 (68%) (P=.035) 相比,新辅助化疗免疫疗法显示出显著的3年OS益处 (77%).
- 新辅助治疗与改善的生存状况相关 (HR 0.70,P=.027) 并在57.5%的患者中实现了病理完整反应或下降阶段.
结论:
- 新辅助化疗免疫疗法对可切除II-IIIBNSCLC的辅助化疗免疫疗法提供了显著的整体生存 (OS) 益处.
- 研究结果表明,新辅助化学免疫疗法对于计划接受全身治疗的患者来说,需要强烈考虑.
- 建议进行进一步的随机试验,以确认这些生存益处.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
05:56Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
808
相关概念视频
01:27Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K